Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-Up Study, 1971???1992

2001 ◽  
Vol 45 (2) ◽  
pp. 121-122
Author(s):  
&NA;
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Cardiovascular Mortality ◽  
Follow Up Study ◽  
Nhanes I

Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: a 4-year follow-up study

2016 ◽  
Vol 123 (12) ◽  
pp. 1399-1402 ◽  
Author(s):  
Maria Teresa Pellecchia ◽  
Riccardo Savastano ◽  
Marcello Moccia ◽  
Marina Picillo ◽  
Pietro Siano ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Uric Acid ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Serum Uric Acid ◽  
Lower Serum ◽  
Follow Up Study ◽  
Early Parkinson’S Disease

scholarly journals The Significance of Follow-Up Serum Uric Acid Levels in Predicting All-Cause Mortality and Cardiovascular Mortality in Peritoneal Dialysis Patients

2021 ◽  
Author(s):  
Pingping Ren ◽  
Qilong Zhang ◽  
Yixuan Pan ◽  
Yi Liu ◽  
Chenglin Li ◽  
...  
Keyword(s):  
Uric Acid ◽  
Peritoneal Dialysis ◽  
Serum Uric Acid ◽  
Cardiovascular Mortality ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Kaplan Meier ◽  
Significant Difference ◽  
All Cause Mortality

Abstract Background: Studies on the correlation between serum uric acid (SUA) and all-cause mortality in peritoneal dialysis (PD) patients were mainly based on the results of baseline SUA. We aimed to analyze the change of SUA level post PD, and the correlation between follow-up SUA and prognosis in PD patients. Methods: All patients who received PD catheterization and maintaining PD in our center from March 2, 2001 to March 8, 2017 were screened. Kaplan-Meier and Cox proportional-hazards regression models were used to analyze the effect of SUA levels on the risks of death. We graded SUA levels at baseline, 6 months, 12 months, 18 months and 24 months post PD by mean of SUA plus or minus a standard deviation as cut-off values, and compared all-cause and cardiovascular mortality among patients with different SUA grades. Results: A total of 1402 patients were included, 763 males (54.42%) and 639 females (45.58%). Their average age at PD start was 49.50±14.20 years. The SUA levels were 7.97±1.79mg/dl at baseline, 7.12±1.48mg/dl at 6 months, 7.05±1.33mg/dl at 12 months, 7.01±1.30mg/dl at 18 months, and 6.93±1.26mg/dl at 24 months. During median follow-up time of 31 (18, 49) months, 173 (12.34%) all-cause deaths occurred, including 68 (4.85%) cardiovascular deaths. There were no significant differences on all-cause mortality among groups with graded SUA levels at baseline, 12 months, 18 months and 24 months during follow-up or on cardiovascular mortality among groups with graded SUA levels at baseline, 6 months, 12 months, 18 months and 24 months during follow-up. At 6 months post PD，Kaplan Meier analysis showed there was significant difference on all-cause mortality among graded SUA levels (c2=11.315, P=0.010), and the all-cause mortality was lowest in grade of 5.65mg/dl≤SUA<7.13mg/dl. Conclusion: SUA level decreased during follow up post PD. At 6 months post PD, a grade of 5.65mg/dl≤SUA<7.13mg/dl was appropriate for better patients’ survival.

Vitamin D Intake and Cardiovascular Mortality in the NHANES I Epidemiological Follow-Up Study Cohort

2012 ◽  
Vol 9 (2) ◽  
pp. 79-89 ◽  
Author(s):  
Chunpeng Fan ◽  
F. Javier Nieto ◽  
Leonelo E. Bautista ◽  
Jason P. Fine
Keyword(s):  
Vitamin D ◽  
Cardiovascular Mortality ◽  
Study Cohort ◽  
Follow Up Study ◽  
Vitamin D Intake ◽  
Nhanes I

scholarly journals AB0926 PERFORMANCE OF THE ACR-EULAR GOUT CLASSIFICATION CRITERIA FOR THE DIAGNOSIS GOUT IN CLINICAL PRACTICE: A ONE-YEAR FOLLOW-UP STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1763.1-1764
Author(s):  
M. Gamala ◽  
J. W. G. Jacobs ◽  
S. Linn-Rasker ◽  
M. Nix ◽  
B. Heggelman ◽  
...  
Keyword(s):  
Uric Acid ◽  
Clinical Practice ◽  
Serum Uric Acid ◽  
Dual Energy ◽  
Classification Criteria ◽  
Dual Energy Ct ◽  
Research Support ◽  
Follow Up Study ◽  
One Year

Background:Classification criteria are used for classifying groups of patients, especially for clinical trials, and diagnostic criteria for diagnosis in individual patients.Objectives:to establish the performance of the 2015 ACR/EULAR gout classification criteria for the diagnosis gout in patients with undifferentiated arthritis. Secondary, to explore the use and efficacy of uric acid lowering therapy (ULT) in daily clinical practice in new gout patients.Methods:1-year follow-up study was performed in subjects with unclassified arthritis, who had been classified as gout patients or not, according the gout classification criteria, including imaging with dual-energy CT, but without ultrasonography and joint X-rays.(1) The reference was the clinical diagnosis (gout yes/no) after 1-year follow-up.Results:71 patients were included; their demographic and clinical characteristics are summarized in Table 1. All 63/71 patients classified as having gout at baseline also had a clinical gout diagnosis after one year, and of the patients not classified, none had the clinical diagnosis of gout at one year.Table 1.Characteristics of the 71subjects included in analysesDiagnosis**gout (n=63)no gout (n=8)Age in years, mean (SD)62 (14)59 (14)Male gender, N (%)53 (84)5 (63)Symptom duration* at baseline in months, median (IQR)12 (1-48)8 (0.5-33)Joint involvement at baseline N patients (%):MTP,33 (52)1 (12)ankle/midfoot12 (19)1 (12)other joint18 (29)6 (76)SUA intercritical in umol/l, mean (SD)484 (63)337 (71)2015 ACR/EULAR criteria baseline score, mean (SD)***10.3 (2.5)2.6 (1.5)2015 ACR/EULAR criteria ≥8 points, N patients (%)***57 (90)0 (0)MSU crystal positive joint aspiration, N patients (%)44 (70)0 (0)DECT positive, N patients (%)49 (78)0 (0)* self-reported, intermittent symptoms; ** all patients classified with gout at baseline also had a clinical gout diagnosis after one yea; *** using a somewhat limited set, see methodsMTP, metatarsophalangeal joints; SUA, serum uric acid; DECT, dual-energy CT; MSU, monosodium urate;.Sensitivity, specificity, positive and negative predictive value, and accuracy values (95% CI) of the classification criteria set we used were 0.91 (0.80-0.96); 1 (0.63-1); 1; 0.57 (0.38-0.74) and 0.92 (0.83-0.97), respectively. The area under the receiver operating characteristics curve (95% CI) was 0.95 (0.91-0.99).ULT was started in 49/63 (78%) of gout patients; 45/49 (92%) of them had serum uric acid levels ≤ 360 μmol/l and no recurrent gout attack during one-year follow-up.Conclusion:The 2015 ACR-EULAR gout classification criteria performed well for the diagnosis gout in clinical practice. Most gout patients had been treated successfully, according to current guidelines.References:[1]Gamala M, Jacobs JWG, Linn-Rasker SF, Nix M, Heggelman BGF, Pasker-de Jong PCM, et al. The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis. Rheumatology 2019 Sep (Epub ahead print).Disclosure of Interests:Mihaela Gamala: None declared, Johannes W. G. Jacobs Grant/research support from: Roche, Suzanne Linn-Rasker: None declared, Maarten Nix: None declared, Ben Heggelman: None declared, Pieternel Pasker: None declared, Jacob M. van Laar Grant/research support from: MSD, Genentech, Consultant of: MSD, Roche, Pfizer, Eli Lilly, BMS, Ruth Klaasen: None declared

scholarly journals Elevated Serum Uric Acid is Associated with Rapid Decline in Kidney Function: A 10-Year Follow-Up Study

2020 ◽  
Vol Volume 13 ◽  
pp. 945-953
Author(s):  
Kittrawee Kritmetapak ◽  
Suranut Charoensri ◽  
Rattrai Thaopanya ◽  
Chatlert Pongchaiyakul
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Kidney Function ◽  
Elevated Serum ◽  
Rapid Decline ◽  
Follow Up Study
Sign in / Sign up

Export Citation Format

Share Document